Skip to main content
Top

01-02-2024 | Radioiodine Therapy | Original Article

Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients

Authors: Paulo Alonso Garcia Alves-Junior, Marise Codeço de Andrade Barreto, Fernanda Accioly de Andrade, Daniel Alves Bulzico, Rossana Corbo, Fernanda Vaisman

Published in: Endocrine

Login to get access

Abstract

Introduction

Differentiated thyroid carcinoma (DTC) is a rare oncological disease in the pediatric population, presenting with a more aggressive form. Stimulated thyroglobulin (sTg) and the 131-iodine whole-body scans (WBSs) are known adult markers related to the presence of distant metastasis. Little is known about their roles in the pediatric population.

Purpose

To evaluate sTg levels and diagnostic WBS (DxWBS) as predictors of distant metastasis after thyroidectomy and to correlate with the response to treatment at the end of follow-up in pediatric DTC.

Materials and methods

Patients under 19 years old diagnosed with DTC from 1980 to 2022 were retrospectively evaluated. sTg values and WBS were assessed after thyroidectomy and prior radioiodine treatment (RIT) and correlated with the possibility of finding distant metastasis and response to treatment at the end of follow-up.

Results

In a total of 142 patients with a median age of 14.6 (4–18) years who were followed for 9.5 ± 7.2 years and classified according to the ATA risk of recurrence as low (28%), intermediate (16%), and high risk (56%), 127 patients had their sTg evaluated. A sTg value of 21.7 ng/dl yielded a sensitivity of 88% compared to 30% for DxWBS in predicting distant metastasis. Specificity was 60% and 100% respectively. 42% of patients obtained discordant results between DxWBS and RxWBS. In high-risk patients, sTg levels were particularly able to differentiate those who would have distant metastasis with better diagnostic accuracy than the WBSs.

Conclusions

The sTg level had better performance in detecting distant metastases in pediatric DTC than the DxWBS. DxWBS’s low performance suggests that caution should be taken in interpreting their findings in terms of the underdiagnosis for metastatic disease, especially when the sTg level already suggests distant disease.
Literature
2.
go back to reference M.O. Bernier, D.R. Withrow, A. Berrington de Gonzalez et al. Trends in pediatric thyroid cancer incidence in the United States, 1998–2013. Cancer 125(14), 2497–2505 (2019)CrossRefPubMed M.O. Bernier, D.R. Withrow, A. Berrington de Gonzalez et al. Trends in pediatric thyroid cancer incidence in the United States, 1998–2013. Cancer 125(14), 2497–2505 (2019)CrossRefPubMed
3.
go back to reference N.V. Balmant, R. De Souza Reis, M. De Oliveira Santos et al. Rare cancers in childhood and adolescence in Brazil: first report of data from 19 population-based cancer registries. Cancer 125, 2638–2646 (2019)CrossRefPubMed N.V. Balmant, R. De Souza Reis, M. De Oliveira Santos et al. Rare cancers in childhood and adolescence in Brazil: first report of data from 19 population-based cancer registries. Cancer 125, 2638–2646 (2019)CrossRefPubMed
4.
go back to reference A. Miranda-Filho, J. Lortet-Tieulent, F. Bray et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225–234 (2021).CrossRefPubMed A. Miranda-Filho, J. Lortet-Tieulent, F. Bray et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225–234 (2021).CrossRefPubMed
5.
go back to reference R. De Souza Reis, G. Gatta, B. De Camargo, Thyroid carcinoma in children, adolescents, and young adults in Brazil: a report from 11 population-based cancer registries. PLoS One 15, e0232416 (2020)CrossRefPubMedPubMedCentral R. De Souza Reis, G. Gatta, B. De Camargo, Thyroid carcinoma in children, adolescents, and young adults in Brazil: a report from 11 population-based cancer registries. PLoS One 15, e0232416 (2020)CrossRefPubMedPubMedCentral
6.
go back to reference J.W. Thiesmeyer, C.E. Egan, J.A. Greenberg et al. Prepubertal children with papillary thyroid carcinoma present with more invasive disease than adolescents and young adults. Thyroid 33, 214–222 (2023)CrossRefPubMed J.W. Thiesmeyer, C.E. Egan, J.A. Greenberg et al. Prepubertal children with papillary thyroid carcinoma present with more invasive disease than adolescents and young adults. Thyroid 33, 214–222 (2023)CrossRefPubMed
7.
go back to reference B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral
8.
go back to reference G.L. Francis, S.G. Waguespack, A.J. Bauer et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25, 716–759 (2015)CrossRefPubMedPubMedCentral G.L. Francis, S.G. Waguespack, A.J. Bauer et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25, 716–759 (2015)CrossRefPubMedPubMedCentral
9.
go back to reference C.A. Lebbink, T.P. Links, A. Czarniecka et al. 2022 European thyroid association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur. Thyroid J. 11, e220146 (2022)CrossRefPubMedPubMedCentral C.A. Lebbink, T.P. Links, A. Czarniecka et al. 2022 European thyroid association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur. Thyroid J. 11, e220146 (2022)CrossRefPubMedPubMedCentral
10.
go back to reference M. Nies, R. Vassilopoulou-Sellin, R.L. Bassett et al. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J. Clin. Endocrinol. Metab. 106, e1683–e1697 (2021)CrossRefPubMed M. Nies, R. Vassilopoulou-Sellin, R.L. Bassett et al. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J. Clin. Endocrinol. Metab. 106, e1683–e1697 (2021)CrossRefPubMed
11.
go back to reference M.T. Parisi, H. Eslamy, D. Mankoff, Management of differentiated thyroid cancer in children: focus on the American thyroid association pediatric guidelines. Semin Nucl. Med 46, 147–164 (2016)CrossRefPubMed M.T. Parisi, H. Eslamy, D. Mankoff, Management of differentiated thyroid cancer in children: focus on the American thyroid association pediatric guidelines. Semin Nucl. Med 46, 147–164 (2016)CrossRefPubMed
12.
go back to reference M.B. Amin, F.L. Greene, S.B. Edge et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017)CrossRefPubMed M.B. Amin, F.L. Greene, S.B. Edge et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017)CrossRefPubMed
13.
go back to reference S.H. Huang, B. O’Sullivan, Overview of the 8th edition TNM classification for head and neck cancer. Curr. Treat. Options Oncol. 18, 40 (2017)CrossRefPubMed S.H. Huang, B. O’Sullivan, Overview of the 8th edition TNM classification for head and neck cancer. Curr. Treat. Options Oncol. 18, 40 (2017)CrossRefPubMed
14.
go back to reference R.C. Webb, R.S. Howard, A. Stojadinovic et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocrinol. Metab. 97, 2754–2763 (2012)CrossRefPubMed R.C. Webb, R.S. Howard, A. Stojadinovic et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocrinol. Metab. 97, 2754–2763 (2012)CrossRefPubMed
15.
go back to reference R. Chou, T. Dana, G.A. Brent et al. Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid 32, 613–639 (2022)CrossRefPubMed R. Chou, T. Dana, G.A. Brent et al. Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid 32, 613–639 (2022)CrossRefPubMed
16.
go back to reference A. Campennì, R.M. Ruggeri, M. Siracusa et al. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur. J. Nucl. Med Mol. Imaging 48, 2466–2475 (2021)CrossRefPubMed A. Campennì, R.M. Ruggeri, M. Siracusa et al. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur. J. Nucl. Med Mol. Imaging 48, 2466–2475 (2021)CrossRefPubMed
17.
go back to reference M.J. Livhits, J.D. Pasternak, M. Xiong et al. Pre-ablation thyroglobulin and thyroglobulin to thyroid-stimulating hormone ratio may be associated with pulmonary metastases in children with differentiated thyroid cancer. Endocr. Pract. 22, 1259–1266 (2016)CrossRefPubMed M.J. Livhits, J.D. Pasternak, M. Xiong et al. Pre-ablation thyroglobulin and thyroglobulin to thyroid-stimulating hormone ratio may be associated with pulmonary metastases in children with differentiated thyroid cancer. Endocr. Pract. 22, 1259–1266 (2016)CrossRefPubMed
18.
go back to reference T. Tian, L. Jiang, X. Zhang et al. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer. Surgery 168, 1095–1100 (2020)CrossRefPubMed T. Tian, L. Jiang, X. Zhang et al. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer. Surgery 168, 1095–1100 (2020)CrossRefPubMed
19.
go back to reference P. Guleria, R. Srinivasan, C. Rana et al. Molecular landscape of pediatric thyroid cancer: a review. Diagnostics (Basel) 12, 3136 (2022)CrossRefPubMed P. Guleria, R. Srinivasan, C. Rana et al. Molecular landscape of pediatric thyroid cancer: a review. Diagnostics (Basel) 12, 3136 (2022)CrossRefPubMed
20.
go back to reference J.N. Gallant, S.C. Chen, C.A. Ortega et al. Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. JAMA Oncol. 8, 1323–1327 (2022)CrossRefPubMedPubMedCentral J.N. Gallant, S.C. Chen, C.A. Ortega et al. Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. JAMA Oncol. 8, 1323–1327 (2022)CrossRefPubMedPubMedCentral
21.
go back to reference A.T. Franco, J.C. Ricarte-Filho, A. Isaza et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. J. Clin. Oncol. 40, 1081–1090 (2022)CrossRefPubMedPubMedCentral A.T. Franco, J.C. Ricarte-Filho, A. Isaza et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. J. Clin. Oncol. 40, 1081–1090 (2022)CrossRefPubMedPubMedCentral
22.
go back to reference K.P. Mollen, A.D. Shaffer, L. Yip et al. Unique molecular signatures are associated with aggressive histology in pediatric differentiated thyroid cancer. Thyroid 32, 236–244 (2022)CrossRefPubMed K.P. Mollen, A.D. Shaffer, L. Yip et al. Unique molecular signatures are associated with aggressive histology in pediatric differentiated thyroid cancer. Thyroid 32, 236–244 (2022)CrossRefPubMed
23.
go back to reference V.A. Paulson, E.R. Rudzinski, D.S. Hawkins, Thyroid cancer in the pediatric population. Genes (Basel) 10, 723 (2019)CrossRefPubMed V.A. Paulson, E.R. Rudzinski, D.S. Hawkins, Thyroid cancer in the pediatric population. Genes (Basel) 10, 723 (2019)CrossRefPubMed
24.
go back to reference A. Rangel-Pozzo, L. Sisdelli, M.I.V. Cordioli et al. Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations. Cancers (Basel) 12, 3146 (2020)CrossRefPubMed A. Rangel-Pozzo, L. Sisdelli, M.I.V. Cordioli et al. Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations. Cancers (Basel) 12, 3146 (2020)CrossRefPubMed
25.
go back to reference J.R.A. Da Silva Breder, P.A.G. Alves, M.L. Araújo et al. Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis? Eur. Thyroid J. 11, e210090 (2022)CrossRefPubMedPubMedCentral J.R.A. Da Silva Breder, P.A.G. Alves, M.L. Araújo et al. Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis? Eur. Thyroid J. 11, e210090 (2022)CrossRefPubMedPubMedCentral
26.
go back to reference L. Sisdelli, M. Cordioli, F. Vaisman et al. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. Pediatr. Blood Cancer 66, e27707 (2019)CrossRefPubMed L. Sisdelli, M. Cordioli, F. Vaisman et al. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. Pediatr. Blood Cancer 66, e27707 (2019)CrossRefPubMed
27.
go back to reference F. Vaisman, D.A. Bulzico, C.H. Pessoa et al. Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer. Clin. (Sao Paulo) 66, 281–286 (2011)CrossRef F. Vaisman, D.A. Bulzico, C.H. Pessoa et al. Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer. Clin. (Sao Paulo) 66, 281–286 (2011)CrossRef
28.
go back to reference A. Cistaro, N. Quartuccio, M.C. Garganese et al. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. Eur. J. Nucl. Med Mol. Imaging 49, 1374–1385 (2022)CrossRefPubMed A. Cistaro, N. Quartuccio, M.C. Garganese et al. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. Eur. J. Nucl. Med Mol. Imaging 49, 1374–1385 (2022)CrossRefPubMed
29.
go back to reference S.A. Gulec, S. Ahuja, A.M. Avram et al. A joint statement from the American thyroid association, the European association of nuclear medicine, the European thyroid association, the society of nuclear medicine and molecular imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid 31, 1009–1019 (2021)CrossRefPubMed S.A. Gulec, S. Ahuja, A.M. Avram et al. A joint statement from the American thyroid association, the European association of nuclear medicine, the European thyroid association, the society of nuclear medicine and molecular imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid 31, 1009–1019 (2021)CrossRefPubMed
30.
go back to reference P.S. Choudhury, M. Gupta, Differentiated thyroid cancer theranostics: radioiodine and beyond. Br. J. Radio. 91, 20180136 (2018)CrossRef P.S. Choudhury, M. Gupta, Differentiated thyroid cancer theranostics: radioiodine and beyond. Br. J. Radio. 91, 20180136 (2018)CrossRef
31.
go back to reference C. Tavares, M.J. Coelho, C. Eloy et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr. Connect 7, 78–90 (2018)CrossRefPubMed C. Tavares, M.J. Coelho, C. Eloy et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr. Connect 7, 78–90 (2018)CrossRefPubMed
32.
go back to reference T. Kogai, G.A. Brent, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharm. Ther. 135, 355–370 (2012)CrossRef T. Kogai, G.A. Brent, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharm. Ther. 135, 355–370 (2012)CrossRef
33.
go back to reference P.E. Bravo, B. Goudarzi, U. Rana et al. Clinical significance of discordant findings between pre-therapy 123I and post-therapy 131I whole body scan in patients with thyroid cancer. Int J. Clin. Exp. Med 6, 320–333 (2013)PubMedPubMedCentral P.E. Bravo, B. Goudarzi, U. Rana et al. Clinical significance of discordant findings between pre-therapy 123I and post-therapy 131I whole body scan in patients with thyroid cancer. Int J. Clin. Exp. Med 6, 320–333 (2013)PubMedPubMedCentral
34.
go back to reference F. Pacini, M. Capezzone, R. Elisei et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab. 87, 1499–1501 (2002)CrossRefPubMed F. Pacini, M. Capezzone, R. Elisei et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab. 87, 1499–1501 (2002)CrossRefPubMed
Metadata
Title
Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients
Authors
Paulo Alonso Garcia Alves-Junior
Marise Codeço de Andrade Barreto
Fernanda Accioly de Andrade
Daniel Alves Bulzico
Rossana Corbo
Fernanda Vaisman
Publication date
01-02-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03691-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.